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Hypoxia promotes chemoresistance in
acute lymphoblastic leukemia cell lines by
modulating death signaling pathways
C. Petit1,2, F. Gouel1, I. Dubus1, C. Heuclin2, K. Roget3† and J. P. Vannier1*†
Abstract
Background: Several studies show that bone marrow (BM) microenvironment and hypoxia condition can promote
the survival of leukemic cells and induce resistance to anti-leukemic drugs. However, the molecular mechanism for
chemoresistance by hypoxia is not fully understood.
Methods: In the present study, we investigated the effect of hypoxia on resistance to two therapies, methotrexate
(MTX) and prednisolone (PRD), in two cell models for acute lymphoblastic leukemia (ALL). To look for an implication
of hypoxia in chemoresistance, cell viability, total cell density and cell proliferation were analyzed. Survival and
death signaling pathways were also screened by “reverse phase protein array” (RPPA) and western blotting
experiments conducted on selected proteins to confirm the results.
Results: We found that hypoxia promotes chemoresistance in both ALL cell lines. The induction of drug-resistance
by hypoxia was not associated with an increase in total cell density nor an increase in cell proliferation. Using RPPA,
we show that chemoresistance induced by hypoxia was mediated through an alteration of cell death signaling
pathways. This protective effect of hypoxia seems to occur via a decrease in pro-apoptotic proteins and an increase
in anti-apoptotic proteins. The results were confirmed by immunoblotting. Indeed, hypoxia is able to modulate the
expression of anti-apoptotic proteins independently of chemotherapy while a pro-apoptotic signal induced by a
chemotherapy is not modulated by hypoxia.
Conclusions: Hypoxia is a factor in leukemia cell resistance and for two conventional chemotherapies modulates
cell death signaling pathways without affecting total cell density or cell proliferation.
Keywords: ALL, Chemoresistance, Hypoxia, Methotrexate, Prednisolone, RPPA
Background
Oxygen levels in bone marrow are very heterogeneous
with levels ranging from 1 to 7 % [1]. Several studies
mention that microenvironment from BM and more
specifically the hypoxia condition can promote the
survival of leukemic cells. Hypoxia plays an important
role in numerous physiological processes, including cell
metabolism, cell survival, cell proliferation, angiogenesis
and in pathological processes, like cancerogenesis, and
metastasis [2–4]. Hypoxia is a negative prognostic and
predictive factor due to its pathological features [5].
Indeed, recently it has been shown that hypoxia contrib-
utes to chemotherapy and radiotherapy resistance of
leukemic cells and that hypoxic areas are associated with
progression of leukemia [6, 7]. Leukemic cells from bone
marrow of childhood acute lymphoblastic leukemia
(ALL) have shown an overexpression of a key marker of
hypoxia called hypoxia inducible factor (HIF-1α). In
normoxic conditions, HIF-1α is degraded by 26S prote-
asome. Conversely, in hypoxic conditions, as often found
in the microenvironment of bone marrow, HIF-1α is sta-
bilized and dimerized with a HIF-1β subunit to activate
the transcription of several genes involved in glucose
metabolism, angiogenesis and cell survival [8]. Thus,
HIF-1α activity is associated with increase of tumor
progression and therapeutic resistance of leukemic cells
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and its stabilization correlates with poor prognosis of
patients [9].
ALL is the most common form of pediatric cancer
(approximately 35 % of childhood cancers). Due to pro-
gress in treatments, the survival rate has increased from
20 % in the 60’s to 70–90 % depending on the leukemia
type. ALL is characterized by a deregulated proliferation
process of a lymphoblastic population blocked at an
immature stage in the BM. Several chemotherapies
blocking the cell cycle and inducing cell death are
currently available for ALL treatment such as vincristine
and methotrexate [10]. Despite improved treatment pro-
tocols and a better management of leukemia patients, a
significant number of patients relapse due to chemother-
apy failure [11, 12]. Relapses of leukemia patients are
due to the persistence of lymphoblastic cells that are
resistant to treatment and already present at the diagno-
sis. The continued presence of these cells has already
been linked to a disruption of the apoptotic pathways
[13, 14], the development of malignant phenotypes and
their chemoresistance [15], and a bad prognosis and
increased risk of relapse [16]. Several explanation of
relapse have been proposed. They include the persist-
ence of blasts out of reach for chemotherapies, leukemic
cells blocked in G0 phase, leukemic cells intrinsic drug
resistance present at diagnosis and leukemic cells with
acquired resistance [17]. Most of these relapses are due
to deregulation of molecular mechanisms. Therefore, the
study of intracellular signaling pathways is essential to
understand chemoresistance in leukemia.
New techniques for proteomic studies such as reverse
phase protein array (RPPA) have been developed to
allow a straightforward screening of signaling pathways
on several protein lysates. The RPPA method allows the
measurement of protein expression levels and their
post-translational states (cleavage, phosphorylation,
ubiquitination) in a low volume of sample. RPPA has
already been used to demonstrate the importance of sev-
eral proteins and their post-translational modification in
tumorogenesis [18, 19].
In our study, two different chemotherapies, metho-
trexate (MTX) and prednisolone (PRD), were used to
evaluate the chemoresistance of leukemic cells. MTX is
a folate analog used in the treatment of childhood
B-ALL and auto-immune disease which is able to inhibit
deoxyribonucleic acid (DNA) synthesis through thymi-
dylate and purine nucleotides depletion [20]. The loss of
DNA precursors by MTX induces DNA strand breakage
and cell death [21, 22]. PRD is a glucocorticoid used to
predict long term clinical outcome of ALL patients
which diffuses passively into the cell and binds to gluco-
corticoid receptor (GR). After dimerization of GR, this
complex acts as a transcription factor able to modify the
expression of many genes [23, 24].
In the present study, we first show that hypoxia envir-
onment enhances the survival of a sub-group of
leukemic cells specific to lymphoid B cells called B-ALL
when treating with chemotherapies, such as MTX and
PRD. The effect of hypoxia is not associated with an
increase of total cell density nor cell proliferation. Then,
using RPPA technology to screen death and survival
signaling pathways we show a deregulation of pro- and
anti-apoptotic pathways. Indeed, in the two B-ALL cell
lines treated with MTX, hypoxia appears to inhibit the
expression of pro-apoptotic proteins (Bax, Bim and
Cleaved Caspase 3) and stimulate the expression of anti-
apoptotic proteins (Bcl-2, Mcl-1). In the case of PRD,
hypoxia seems to stimulate the expression of anti-
apoptotic proteins (Bcl-2, Mcl-1 and XIAP). Results
from western blotting experiments confirm that hypoxia
is able to modulate the expression of anti-apoptotic
proteins (Mcl-1 and Bcl-2). However, an up regulation
of a pro-apoptotic protein (Bim) induced by a chemo-
therapy is not modulated by hypoxia.
Altogether, these results suggest that hypoxia can
modulate the expression of pro and anti-apoptotic
proteins allowing chemotherapy resistance in B-ALL
cells and might play a role in patient relapse. Hypoxia,
and to some extend HIF-1alpha, might represent a
good therapeutic target for future drug development in
addition to traditional chemotherapies. Indeed, a
combined treatment of specific inhibitor of HIF-1alpha
(P3155 or EZN-2968) with a classical chemotherapy
could block the up-regulation of anti-apoptotic proteins
pre-stimulated by the bone marrow environment and
induce the over-expression of pro-apoptotic proteins.
Methods
Cell culture and treatments
The human leukemic cell lines Nalm-6 and Reh
(DSMZ®, Braunschweig, Deutschland) were cultured in
RPMI 1640 medium (Eurobio®, Courtaboeuf, France)
containing 10 % fetal bovine serum (FBS, Eurobio®),
2 mM of L-glutamine (Eurobio®) with 5000 UI/L peni-
cillin and 50 mg/L streptomycin (Eurobio®). Nalm-6
and Reh cell lines were maintained at 37 °C in a 5 %
CO2 humidified atmosphere. Normoxic experiments
at 37 °C were carried out under normal atmospheric
conditions (21 % O2, 5 % CO2) while hypoxic experi-
ments at 37 °C used a chamber (modified Anaerobic
System Model 1029, Fisher Scientific®, Illkirch, France)
giving 5 % O2, 5 % CO2, qs N2 (Air Products®, Paris,
France). Methotrexate (MTX; (2S)-2-[[4-[(2,4-diami-
nopteridin-6-yl) methyl-methylamino] benzoyl]- amino]
pentadioic acid) was obtained from a commercial source
(Sigma-Aldrich®, Saint-Quentin Fallavier, France). Several
concentrations were used 10 nM, 100 nM, 500 nM, 1 μM
and 100 μM; two controls were added (culture media with
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or without solvent (NaCl 0.1 M). Prednisolone (PRD; Cor-
ticoïd) used for the study was from a commercial source
(Sigma-Aldrich®). Several concentrations were used 10
nM, 100 nM, 1 μM, 10 μM and 100 μM; two controls
were added: culture media with or without solvent
(water).
Validation of antibodies
Each candidate antibody was subjected to a stringent
validation procedure before being certified for a use in
RPPA. The antibodies had to have an analyte specific
single band in Western blot against our cell line without
non-specific binding. Antibodies selected: All antibodies
mentioned here were validated by immunoblotting: Akt;
P-Akt; Atg 3; Atg 5; Bak; Bax; Beclin-1; Bim; Total Cas-
pase 3; Cleaved Caspase 3; Total Caspase 7; Cleaved
Caspase 7; Total Caspase 8; Cleaved Caspase 8; Total
Caspase 9; Cleaved Caspase 9; Cyclophilin A; Total Erk;
P-Erk; P-FADD; Fas; HIF-1alpha; LC3A; LC3B; MCL-1;
Total mTOR; P-mTOR; Puma; PTEN; p53; Total SAPK;
P-SAPK; XIAP (Ozyme®, Saint-Quentin en Yvelines,
France); Bcl-2 (Dako®, Les Ullis, France); β-Actine
(Sigma-Aldrich®); Ki-67 (Santa Cruz, Heidelberg, Alle-
magne). The secondary antibodies used for our study
were labeled with a marker emitting in the near infrared
(680 nm) (Li-Cor Biosciences®, Nebraska, USA).
Cell survival measurement
Nalm-6 and Reh cells were seeded onto a 48-well
plate at 1×106/mL cells per well (BD FalconTM, BD
Biosciences®, Le Pont de Claix, France), stored under
normoxic or hypoxic conditions for 24 h, then treated
with different concentrations of MTX or PRD under
the same conditions and harvested at 24, 48 and
72 h. Cells were subsequently treated with one of 2
solutions: propidium iodide to determine the number
of non-viable cells; detergent to determine the total
number of cells. The viable cell density (total cell
number multiplied by percentage of viable cells) and
percentage of viable cells were read with an ADAM
series automatic cell counter (Labtech®, Palaiseau,
France). All data from cell survival measurements are
presented as the mean ± the standard error of the
mean (S.E.M.) Significant differences were determined
by two-way ANOVA with a Bonferroni post-test using
GraphPad Prism version 5.0 for Windows (GraphPad
Software®, California, USA). Significant differences for
cell viability measurements were determined by a
Student’s paired t-test using GraphPad Prism version
5.0 for Windows (GraphPad Software®).
Cell proliferation measurement
Nalm-6 and Reh cells were loaded with carboxy-
fluorescein diacetate succinimidyl ester (CFDA SE,
Fisher Scientific®) and seeded onto a 24-well plates at 1 ×
106/mL cells per well (BD FalconTM, BD Biosciences®),
then stored 24 h under normoxic or hypoxic conditions
before incubation with MTX or PRD over 1, 2, 3 and
6 days in the same a normoxic or hypoxic environment.
Cell division was determined by monitoring CFDA SE
using a FACSCalibur (BD Biosciences®). Regarding the
loading of the cell with CFDA SE, briefly, leukemic cells
were centrifuged to obtain cell pellets. Pellets were resus-
pended with phosphate buffer saline (PBS 1X, Eurobio®)
containing 0.1 % of bovine serum albumin (BSA, Eurobio®,
Courtaboeuf, France). 10 mM of freshly prepared CFDA
SE in dimethylsulfoxide (DMSO, Sigma-Aldrich®) was
then added to Nalm-6 and Reh cell suspension to obtain a
final working concentration of 10 μM before incubation at
37 °C for 15 min. To quench the staining reaction, 5 vol-
umes of ice-cold culture media were added directly to the
cell suspension and left for 5 min on ice. Cells were centri-
fuged at 1500 rpm during 5 min and the pellets resus-
pended with fresh culture media a total of three times.
After diffusion into the cytoplasm of the leukemic cells
CFDA SE was measured with a flow cytometer with
488 nm excitation and the data analysed using FlowJo
software (TreeStar, Oregon, USA, Version 9.6). Acquisi-
tion based on 10,000 events (cells) was performed for each
analysis.
Reverse phase protein array
Spotting
The method used in this study has been described previ-
ously [25] (Additional file 1: Protocol S1). Briefly, RPPA
assay was performed on 1 mg/mL of protein lysed with
20 mM of Hepes (pH7.9, Sigma-Aldrich®), 1 mM of MgCl2
(Sigma-Aldrich®), 1 % of NP-40 substitute (VWR®,
Fontenay-Sous-Bois, France), 0.5 % of Sodium cholate
(Sigma-Aldrich®), 0.25 % of n-dodecyl-β-D-maltoside
(VWR®), 1 mM of Sodium orthovanadate (Sigma-Aldrich®)
and 50 mM of Sodium fluoride (Sigma-Aldrich®) contain-
ing freshly added protease inhibitors and phosphatase in-
hibitors (Fisher Scientifics®, Illkirch, France). Lysed protein
was mixed with 4X printing buffer [250 mM Tris (Sigma-
Aldrich®), 50 % (v/v) Glycerol (Sigma-Aldrich®), 4 % (v/v)
SDS (Sigma-Aldrich®), 10 % (v/v) 2-mercaptoethanol
(Sigma-Aldrich®), 0.1 % (v/v) Tween 20 (Sigma-Aldrich®) in
ddH20]. Protein samples were printed onto nitrocellulose-
coated glass slides (Sartorius®, Aubagne, Germany) with a
SpotBot® 3 arrayer (Arrayit Corporation®, California, USA)
and stocked overnight at 4 °C.
Hybridization
Slides were blocked with 50 % Odyssey blocking buffer
(Li-Cor Biosciences ®) in PBS 1x for 1 h. Slides were
incubated for 2 h with primary antibodies diluted at
1:100 and subsequently washed four times for 5 min in
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PBS 1x with 0.1 % Tween-20. Next, slides were incu-
bated with infrared-labeled secondary antibody diluted
at 1:2000 for 1 h in the dark. Washing steps were
performed as described above. All washing and incuba-
tion steps were carried out at room temperature with
gentle shaking. Finally, slides were rinsed in water and
air-dried at room temperature. Slides were scanned
with an Innoscan 710-IR infrared microarray scanner
(Innopsys®, Carbonne, France) with 10 μm resolution
and wavelength 670 nm.
Analysis
Analysis was performed on Mapix Software (Innopsys®).
Background and non-specific binding was subtracted
from total signal intensity for each spot. RPPA data were
expressed as a Z score and values below or above two
standard deviations away from the mean were analyzed.
For Heatmap representations, a hierarchical clustering
(Ward method) was performed on an open source soft-
ware R. The hierarchical clustering calculation was based
on an Euclidean distance method.
Western blot Western immunoblotting analyses were
done using material from 5 × 105 to 10 × 106 cells.
Briefly, cells were washed in PBS, harvested, and solubi-
lized in aforementioned lysis buffer and kept on ice for
20 min. Lysates were centrifuged at 10,000 g for 15 min
at 4 °C and stocked at −80 °C. Protein lysates were dosed
with BCA protein assay kit (Thermo Scientific®, Illkirch,
France, [26]. 30 μg of proteins were diluted in loading buf-
fer, heated for 5 min at 95 °C, size-separated in a 4–20 %
pre-cast polyacrylamide gel (Fisher Scientifics®), and trans-
ferred to nitrocellulose membranes (GE Healthcare®,
Aulnay sous Bois, France). Membranes were blocked with
aforemention blocking buffer, washed, and incubated with
the previously mentioned antibodies in blocking buffer +
0.1 % of Tween-20 (Sigma-Aldrich®). Primary antibodies
were used at 1:250 to 1:1000 dilutions. Infrared-coupled
secondary antibodies (IR-Dye680, Li-Cor Biosciences®)
were used at 1:5000 dilutions. Membranes are visualized
and analyzed on the Odyssey imaging system from Li-Cor
(Li-Cor Biosciences®).
Results
MTX and PRD reduce leukemic cells viability in normoxic
conditions
In regard to the effect of MTX and PRD on leukemic
B-ALL cells (Nalm-6 and Reh) cultured in normoxic
conditions (21 % O2), viable cell density was significantly
reduced in a time- and dose-dependent manner. Reh
cells appear to be more resistant than Nalm-6 cells to
both chemotherapies (Fig. 1a). A significant decrease in
living cell density was observed for doses ≥ 100 nM
MTX or 10 nM PRD in Nalm-6 cells and was mainly
due to a decrease in cell viability compared to untreated
cells (Fig. 1b). Reh viability was decreased by doses ≥ 100
nM MTX or 1 μM PRD (Fig. 1b) but living cell density
was unaffected by PRD, suggesting that resistant cells
maintain a proliferative activity even in the presence of
high doses of corticoids (Fig. 1a).
Hypoxia moderates the effect of MTX and PRD on
leukemic cells without affecting viable cell density
To investigate the effect of hypoxia on viable cell density
and cell viability, Nalm-6 and Reh cells were cultured
for 24 h under 5 % or 21 % O2 and then treated for 72 h
with MTX or PRD at different concentrations. Nalm-6
and Reh cells exhibit the same sensitivity to MTX and
PRD in both oxygenation conditions (Fig. 2a). However,
in both cell lines, the decrease in cell viability was less
pronounced under hypoxia than in normoxic conditions
for PRD, and in the case of MTX for the Nalm-6 cell line
(Fig. 2b). These observations suggest that hypoxia has a
protective effect on leukemic cells that is not due to an
increase in the number of viable cells. Furthermore, when
checking leukemic cell proliferation, we observed no
differences for different oxygen microenvironments in the
absence of treatment (Additional file 2: Figure S1.a). After
treatment with MTX, cell proliferation seems to be
reduced in both cell lines while with PRD there is no effect
(Additional file 2: Figure S1.b).
Hypoxia inhibits chemotherapy-induced cell death path-
ways in leukemic cells
To understand how hypoxia can protect leukemic cells
from cell death induced by chemotherapies, apoptotic
pathways were screened by RPPA in both cell lines.
RPPA is an innovative technology allowing a screening
of several molecular pathways on numerous samples. In
this experiment, apoptosis pathways and proliferation /
survival pathways were screened by RPPA. Nalm-6 and
Reh cells were either untreated or treated with several
concentrations of MTX (10nM – 100 μM) and PRD
(10nM – 10 μM) over 24 h in both environments.
In Nalm-6 cells treated with MTX, a shift in protein ex-
pression profile was observed in hypoxia toward normoxia
(See figure on previous page.)
Fig. 1 MTX and PRD inhibit leukemic cells viability in normoxia condition. a Effect of several concentrations of MTX or PRD over 72 h on viable
cell density in normoxia (21 % O2) on leukemic cells. b Effect of several concentrations of MTX or PRD over 72 h on percentage of cell viability in
normoxia (21 % O2) on leukemic cells. Viable cell density and percentage of cell viability measurement were performed by an automatic cell
counter. All results are representatives with mean ± S.E.M. of 4 independent experiments. *indicates p < 0.05; **p < 0.01; ***p < 0.001 vs 0 h
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(Data not shown). In normoxia, the expression profile of
pro-apoptotic proteins was increased in a dose- and time-
dependent manner. Pro-apoptotic proteins (Cleaved
Caspase 3, Bax and Bim) were over-expressed after MTX
treatment in normoxic conditions (more than 2 standard
deviations (SD) away from the mean) while in hypoxic
conditions those three pro-apoptotic proteins were down-
regulated (more than 2 SD away from the mean) (Fig. 3a).
A shift in anti-apoptotic protein expression profile was
observed in hypoxia toward normoxia (Fig. 3b).
In Reh cells treated with MTX, a drop in protein
expression was observed in hypoxia compared to nor-
moxia (Data not shown). Pro-apoptotic proteins (Cleaved
Caspase 7, Bax, Puma and Bim) were over-expressed after
MTX treatment in normoxia (more than 2 SD away from
the mean) (Fig. 4a). Anti-apoptotic proteins (XIAP, Mcl-1
and Bcl-2) were over-expressed after MTX treatment in
hypoxia (more than 2 SD away from the mean) (Fig. 4b).
In Nalm-6 cells treated with PRD, the protein expres-
sion profiles were unchanged by hypoxia and normoxia
(Data not shown). Two pro-apoptotic proteins (cleaved
Caspase 3 and Puma) and autophagy protein (LC3A)
were over-expressed after PRD treatment in normoxia
(more than 2 SD away from the mean) while in hypoxia
three anti-apoptotic proteins (XIAP, Mcl-1 and Bcl-2)
were up-regulated (more than 2 SD away from the
mean) (Fig. 5a and b).
In Reh cells treated with PRD, the protein expression
profiles were unchanged by hypoxia and normoxia (Data
not shown). In normoxia, at least three pro-apoptotic
proteins (Bax, Bim and cleaved caspase 3) and two
autophagy proteins (LC3A and LC3B) were up-regulated
(more than 2 SD away from the mean) (Fig. 6a). The ex-
pression profile of anti-apoptotic proteins was markedly
increased in hypoxia compared to normoxia (Fig. 6b).
To summarize, chemotherapies in normoxia induce an
up-regulation of pro-apoptotic proteins while chemo-
therapies in hypoxia induce an up-regulation of anti-a-
poptotic proteins. All data point were also analyzed and
represented in hierarchical clusters (Additional file 3:
Figures S2, Additional file 4: Figures S3, Additional file 5:
Figures S4, Additional file 6: Figures S5).
Hypoxia promotes anti-apoptotic signals in leukemic cells
independently of chemotherapies
To confirm the hypoxia condition in the experimental set-
tings, HIF-1α expression (a classical marker of hypoxia)
was analysed by western blotting on nuclear protein ex-
tract from Nalm-6 cells maintained either in normoxia or
hypoxia environment over 48 h (Fig. 7a). An over-
expression of HIF-1a was clearly observed after 6 h in
hypoxia condition.
To confirm results obtained by RPPA, the expression
of two anti-apoptotic proteins (Mcl-1 and Bcl-2) and
one pro-apoptotic protein (Bim) were also studied in
western blotting experiments. In untreated Nalm-6 cells,
anti-apoptotic proteins (Mcl-1 and Bcl-2) were up-regu-
lated in hypoxia. After MTX or PRD treatment, similar
results were obtained in Nalm-6 cells in hypoxia (Fig. 7b).
The pro-apoptotic protein Bim was decreased in un-
treated Nalm-6 cells in hypoxia compared to normoxia,
while in MTX or PRD treated Nalm-6 cells no decrease
in Bim expression was observed. Indeed, the intensity of
signal was slightly increase compared to untreated
Nalm-6 in normoxia (Fig. 7b). In untreated and MTX or
PRD treated-Reh cells, the anti-apoptotic protein Mcl-1
was up-regulated in hypoxia while the other anti-
apoptotic protein Bcl-2 has similar level of expression
compared to normoxia (Fig. 7b). The expression of the
pro-apoptotic protein Bim was not affected in untreated
and MTX or PRD treated-Reh cells in hypoxia and nor-
moxia (Fig. 7b).
Mcl-1 was up-regulated for both cell lines under
hypoxia, without or with chemotherapies while Bcl-2
was up-regulated in hypoxia without or with chemother-
apies in Nalm-6 cells only. Bim was down-regulated in
hypoxia in the absence of chemotherapies in Nalm-6
cells only. In treated-Nalm-6 cells, Bim expression was
increased compared to the untreated condition. In
treated-Nalm-6 cells, Bim expression level was similar in
both environments. These results were confirmed by
western blotting quantification (Fig. 7c).
These results indicate that the increase in the expres-
sion of the anti-apoptotic proteins Mcl-1 and Bcl-2 is
hypoxia dependent and chemotherapy independent. The
data also show that the decrease in the expression of the
pro-apoptotic protein Bim was hypoxia dependent in the
absence of treatment while in the presence of treatment,
the increase in the expression of Bim is not dampened
by hypoxia.
Discussion
Resistance to chemotherapy is associated with a bad
prognosis in B-ALL and molecular mechanisms
(See figure on previous page.)
Fig. 2 Hypoxia dampens MTX and PRD effect on leukemic cells viability without affecting viable cell density. a Effect of hypoxia (5 % O2) on
viable cell density of leukemic cells treated with several concentrations of MTX or PRD at 72 h. b Effect of hypoxia (5 % O2) on viability of
leukemic cells treated with several concentrations of MTX or PRD at 72 h. Viable cell density and percentage of cell viability measurement were
performed by an automatic cell counter. All results are representatives with mean ± S.E.M. of 4 independent experiments. *indicates p < 0.05;
**p < 0.01; ***p < 0.001 vs normoxia (21 % O2)
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responsible for this resistance are poorly understood
[27]. Indeed, drug resistance plays a crucial role in re-
lapse of childhood ALL [28, 29]. MTX and PRD are two
chemotherapies widely used in multi-drug treatment of
leukemia [30]. Despite a clear and highly significant
effect of these two molecules on childhood remission
there is still relapse in 10 to 15 % of cases. Considering
the importance of MTX and PRD in contemporary ALL-
treatment protocols, elucidating the mechanisms in-
volved in drug-resistance is of major clinical importance
[31, 32]. MTX is a folic acid analog able to inhibit the de
novo synthesis of purine and pyrimidine bases of DNA
(DesoxyriboNucleic Acid) while PRD is a glucocorticoid
able to regulate the transcription of numerous genes
implicated in cell-cycle arrest and apoptosis of leukemic
cells. Several studies have shown that a deregulation
of protein expression could improve cancer cell
survival after a chemical stress [33]. Protein expres-
sion modification can affect cell signaling pathways
leading to alteration of the energy metabolism (glycolytic
enzymes), ionic movement (calcium flux), cell motility
(cytoskeletal proteins) and cell death mechanisms (apop-
tosis proteins) [34–36]. Others studies have shown that
cancer cells could interact with the microenvironment
[37, 38]. Nefedova et al. explains that microenvironment
could alter the sensitivity of cancer cells to cytotoxic drugs
or radiation [37]. This team shows that multiple interac-
tions including cell-cell, cell-growth factor (soluble fac-
tors) and cell-extracellular matrix (molecular components
and bone marrow environment) are able to influence cell
survival. In leukemia, the interaction between cancer cells
and microenvironment can lead to an improvement of cell
survival and resistance to chemotherapies [39].
In hematological malignancies, leukemic cells have a
strong interaction with BM microenvironment. Benito
group has shown that the expansion of leukemic cells is
increased in low O2 BM condition (hypoxia) [3].
Hypoxia plays a key role in BM microenvironment by
modulating energy metabolism, angiogenesis and
leukemic cell apoptosis. Only a few studies highlight the
involvement of the microenvironment and low oxygen
content in the deregulation of apoptotic process and
resistance of leukemic blasts to chemotherapies. Within
the BM, many hematopoietic niches provide a sanctuary
for leukemic stem cells which evade chemotherapy-
induced cell death and allow the acquisition of a drug-
resistant phenotype [40]. Despite the well-established
role of hypoxia in the acquisition of pro-survival proper-
ties and resistance to chemotherapies of ALL cells, the
molecular mechanisms affected by hypoxia have not
been completely elucidated [41]. It has been shown
that the transcription factor hypoxia-inducible factor-
1alpha (HIF-1alpha) is stabilized in hypoxic conditions
and many participate in the inhibition of leukemic cell
proliferation without promoting cell death. As shown in
recent studies, hypoxia plays an important role in quies-
cence and the intrinsic properties of hematopoietic and
leukemic stem cells [42, 43]. Frolova group also demon-
strate that hypoxia can induce a resistance of ALL cell
lines to several chemotherapies through a stabilization of
HIF-1α. In our study, we have shown that a low level of
O2 is able to induce leukemic cell resistance to chemo-
therapies (Fig. 2b).
Two hypothesis might explain this improvement of
cell viability: an increase in cell proliferation or a better
cell survival. We have found that leukemic cell prolifera-
tion measured by flow cytometry is not affected by hyp-
oxia. To study cell survival, death signaling pathways were
analyzed by RPPA. Cell death is part of the hematopoietic
homeostasis. However, a deregulation of cell death mecha-
nisms can disrupt the delicate equilibrium between cell
proliferation, survival and death and can lead to the devel-
opment of diseases (cancers, auto-immune diseases and
neurodegenerative diseases). Several studies have shown
that apoptotic pathway alterations could play a role in the
induction of chemotherapy resistance in leukemia [44].
Testa group explain that in acute myeloid leukemia
(AML) the alteration of apoptotic pathway with an induc-
tion of anti-apoptotic signals through p53 or Bcl-2 can
promote survival of leukemic cells. Chetoui’s group
demonstrated that Mcl-1, an anti-apoptotic protein from
the Bcl-2 family that is regulated by extracellular signal-
regulated kinases (ERK) signaling pathway, contributes
significantly to the drug resistance of melanoma cells [45].
Furthermore, other studies show that overexpression of
anti-apoptotic proteins such as inhibitor of apoptosis pro-
teins (IAPs) may contribute to the development of cancer
[46]. X-linked inhibitor of apoptosis protein (XIAP) is the
best-defined of IAP family member able to neutralize
directly the effector caspase 3. The XIAP protein level
correlated with the sensitivity to multiple anti-cancer
drugs. For example in AML, patients with lower levels of
XIAP protein had a better survival rate and a tendency
toward longer remission than those with higher levels of
(See figure on previous page.)
Fig. 3 Hypoxia inhibits MTX-induced cell death pathways in Nalm-6 cells. a Effect of several concentrations of MTX over 24 h on Nalm-6 cells
maintained in normoxia (21 % O2) or in hypoxia (5 % O2) on 10 pro-apoptotic proteins. b Effect of several concentrations of MTX over 24 h on
Nalm-6 cells maintained in normoxia (21 % O2) or in hypoxia (5 % O2) on 3 anti-apoptotic proteins. Proteomic analysis was performed by RPPA.
Data are represented by experimental conditions and by protein expressions after Z-score normalization. Protein expressions with two standard
deviations away from the mean were analyzed
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Fig. 4 Hypoxia inhibits MTX-induced cell death pathways in Reh cells. a Effect of several concentrations of MTX over 24 h on Reh cells maintained in
normoxia (21 % O2) or in hypoxia (5 % O2) on 10 pro-apoptotic proteins. b Effect of several concentrations of MTX over 24 h on Reh cells maintained in
normoxia (21 % O2) or in hypoxia (5 % O2) on 3 anti-apoptotic proteins. Proteomic analysis was performed by RPPA. Data are represented by experimental
conditions and by protein expressions after Z-score normalization. Protein expressions with two standard deviations away from the mean were analyzed
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Fig. 5 Hypoxia inhibits PRD-induced cell death pathways in Nalm-6 cells. a Effect of several concentrations of PRD over 24 h on Nalm-6 cells
maintained in normoxia (21 % O2) or in hypoxia (5 % O2) on 11 pro-apoptotic and autophagy proteins. b Effect of several concentrations of PRD
over 24 h on Nalm-6 cells maintained in normoxia (21 % O2) or in hypoxia (5 % O2) on 3 anti-apoptotic proteins. Proteomic analysis was performed by
RPPA. Data are represented by experimental conditions and by protein expressions after Z-score normalization. Protein expressions with two standard
deviations away from the mean were analyzed
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Fig. 6 Hypoxia inhibits PRD-induced cell death pathways in Reh cells. a Effect of several concentrations of PRD over 24 h on Reh cells maintained
in normoxia (21 % O2) or in hypoxia (5 % O2) on 11 pro-apoptotic and autophagy proteins. b Effect of several concentrations of PRD over 24 h
on Reh cells maintained in normoxia (21 % O2) or in hypoxia (5 % O2) on 3 anti-apoptotic proteins. Proteomic analysis was performed by RPPA.
Data are represented by experimental conditions and by protein expressions after Z-score normalization. Protein expressions with two standard
deviations away from the mean were analyzed
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Fig. 7 (See legend on next page.)
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XIAP [47]. Our screening by RPPA has shown modifica-
tion of apoptotic protein expression in hypoxia. Chemo-
therapies usually induce an increase of pro-apoptotic
proteins (Bax, Bim and Caspase 3) and a decrease of anti-
apoptotic proteins leading to cancer cell death. Surpris-
ingly, in hypoxia, we observed an increase in anti-
apoptotic signals (Bcl-2, Mcl-1 and XIAP) and a decrease
in pro-apoptotic signals in drug-treated leukemic cell
(Figs. 3 to 6). This observation was confirmed by RPPA and
western blotting. This data shows that a low O2 content is
able to directly modify cell death protein expression. Fur-
thermore, an increase of anti-apoptotic proteins (Mcl-1 and
Bcl-2) is already present in hypoxia in the absence of che-
motherapies indicating a basal direct effect of hypoxia in
favor of leukemic cell survival (Fig. 7). One hypothesis is
that hypoxia is able to condition leukemic cells to thera-
peutic stress by tuning their intrinsic survival capacity. HIF-
1alpha stabilized in hypoxia is a key factor in cancer cells
and is associated with worse prognosis in many cancers.
HIF-1alpha is a transcription factor able to induce the
expression of death signaling pathway. Indeed, hypoxia
has also been reported to inhibit apoptosis in several
experimental conditions. The work of Dons et al. have
shown that hypoxia could protect kidneys from
staurosporine-induced apoptosis with an induction of
IAP-2 protein [48]. Jin’s group have observed that hyp-
oxia is able to prevent serum deprivation-induced
apoptosis of tumor cells by decreasing the Bax/Bcl-2
ratio and inhibiting the caspase 3 activity [49]. As
shown in our summary chart, we demonstrate that hyp-
oxia potentiates leukemic cell resistance to chemother-
apies (MTX and PRD) directly by induction of
expression of multiple anti-apoptotic proteins such as
Bcl-2 and Mcl-1 simultaneously (Table 1). This
(See figure on previous page.)
Fig. 7 Hypoxia promotes anti-apoptotic signals in leukemic cells independently of chemotherapies. a Effect of hypoxia (5 % O2) over 48 h on
nuclear expression of HIF-1α protein in Nalm-6 cells. b Nalm-6 and Reh cells were cultured either in normoxia or hypoxia and untreated or treated
with MTX or PRD for 3 h and lysed. Equal amounts of proteins were fractionated by SDS-PAGE and Western blotted with anti-Mcl-1, anti-Bcl-2,
anti-Bim and anti-β actin. c Western blotting quantification was performed on the image from Fig. 7B
Table 1 Summary chart of results obtained in this study
Nalm-6 no treatment
Cell density Cell proliferation Cell viability (%) MCL-1 protein expression Bcl-2 protein expression Bim protein expression
Normoxa More important Equal Equal Weakly expressed Weakly expressed Overexpressed
Hypoxia Less important Equal Equal Overexpressed Overexpressed under expressed
Nalm-6 treated MTX
Cell density Cell proliferation Cell viability (%) MCL-1 protein expression Bcl-2 protein expression Bim protein expression
Normoxa inhibited by MTX inhibited by MTX inhibited by MTX Overexpressed Overexpressed Equal
Hypoxia inhibited by MTX inhibited by MTX Less inhibited strongly expressed strongly expressed Equal
Nalm-6 treated PRD
Cell density Cell proliferation Cell viability (%) MCL-1 protein expression Bcl-2 protein expression Bim protein expression
inhibited by PRD Equal inhibited by PRD Overexpressed Overexpressed Equal
inhibited by PRD Equal Less inhibited strongly expressed strongly expressed Equal
Reh no treatment
Cell density Cell proliferation Cell viability (%) MCL-1 protein expression Bcl-2 protein expression Bim protein expression
Normoxia More important Equal Equal Overexpressed Overexpressed Equal
Hypoxia Less important Equal Equal strongly expressed strongly expressed Equal
Reh treated MTX
Cell density Cell proliferation Cell viability (%) MCL-1 protein expression Bcl-2 protein expression Bim protein expression
Normoxia inhibited by MTX inhibited by MTX inhibited by MTX Overexpressed Overexpressed Equal
Hypoxia inhibited by MTX inhibited by MTX inhibited by MTX strongly expressed strongly expressed Equal
Reh treated PRD
Cell density Cell proliferation Cell viability (%) MCL-1 protein expression Bcl-2 protein expression Bim protein expression
Normoxia inhibited by PRD Equal inhibited by PRD Overexpressed Overexpressed Equal
Hypoxia inhibited by PRD Equal Less inhibited strongly expressed strongly expressed Equal
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modification of protein expression is responsible for an
increase in leukemic cells survival and could play a role
in treatment failure.
Conclusions
Our data clearly demonstrate an important role of low
oxygen level in the response to treatment of leukemic cells. It
appears that hypoxia is able to improve leukemic cell survival
without modification of proliferation activities and that envir-
onmental conditions can modulate the protein expression of
cancer cells. With our screening method of death signaling
pathways, we demonstrate that hypoxia can increase the
expression of anti-apoptotic proteins Mcl-1 and Bcl-2. This
over-expression of anti-apoptotic proteins could contribute to
the phenomenon of drug resistance of leukemic cells and
treatment failure. Hypoxia and especially the increase in anti-
apoptotic proteins Mcl-1 and Bcl-2 should be taken into
account in the development of new chemotherapies and the
design of new therapeutic strategies.
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